Tag Archives: Sorafenib

Bayer seeks to stay the operation of the CL order – files appeal against the grant of the CL, before the IPAB in Chennai (India)

Posted on May 18, 2012 by

Acting on its press statement, German pharmaceutical company Bayer has filed an appeal against the Compulsory License (CL) order before the Intellectual Property Appellate Board (IPAB) in Chennai and has in particular sought to have the operation of the CL … Continue reading →

Posted in Compulsory Licensing, Indian Patent Law | Tagged , , , | Leave a comment

Cipla slashes prices of anticancers in India

Posted on May 7, 2012 by

Source: Scrip Intelligence 03 May 2012, Anju Ghangurde Cipla has announced price cuts of about 60% or more across a clutch of oncology products, including its generic version of AstraZeneca’s lung cancer therapy, Iressa (gefitinib), in India. Cipla said that it … Continue reading →

Posted in Drug Pricing | Tagged , , , , , | Leave a comment

Patent office may grant CL in future if circumstances demand so: Patent Controller

Posted on March 28, 2012 by

Source: www.pharmabiz.com Tuesday, 27 March,2012 With respect to safeguarding of public interest and to ensure availability of life saving drugs at affordable prices, Patent office informed that they may certainly consider accepting Compulsory Licence (CL) applications in future also, if … Continue reading →

Posted in Compulsory Licensing, TRIPS | Tagged , , | 1 Comment

Novartis challenges India’s patent law

Posted on March 28, 2012 by

Source: www.nature.com 21 March 2012 Drug company up for rematch against clause prohibiting indefinite extension of patents. Pharmaceutical giant Novartis goes to the Indian Supreme Court next week, aiming to weaken the country’s drug-patent law by challenging a clause that … Continue reading →

Posted in Compulsory Licensing, HIV/Aids, Indian Patent Law, TRIPS | Tagged , , | Leave a comment

One important step forward for access to medicines in India, but are two giant steps backwards just around the corner?

Posted on March 28, 2012 by

Source: www.oxfamamerica.com March 23rd, 2012 Cross posted from Global Health Check and written by Rohit Malpani and Mohga M Kamal-Yanni. Rohit Malpani is a campaigns advisor at Oxfam and leads the organization’s access to medicines campaign. Mohga M Kamal-Yanni works … Continue reading →

Posted in Compulsory Licensing, HIV/Aids, Indian Patent Law | Tagged , , | Leave a comment

How To Charge $1.6 Million For a New Drug And Get Away With It

Posted on March 21, 2012 by

Source: www.forbes.com 19 March 2012 Call it a warning shot: last week an Indian patent court shocked the $600 billion global pharmaceutical business by ordering Bayer, the German health care giant, to allow a tiny Indian generic drug company to … Continue reading →

Posted in Generic drug, Indian Patent Law | Tagged , , | Leave a comment

India Affirms Role as Developing World’s Pharmacy

Posted on March 21, 2012 by

Source: www.ipsnews.net Mar. 19, 2012 India’s generic pharmaceutical industry meets 70 percent of domestic demand and exports 11 billion dollars worth of generic drugs annually. NEW DELHI,  (IPS) – By allowing a generic manufacturer to produce a patented cancer drug … Continue reading →

Posted in Compulsory Licensing, Indian Patent Law, TRIPS flexibilities | Tagged , , | Leave a comment

Natco victory could encourage other generic companies also to apply for compulsory licence

Posted on March 19, 2012 by

Source: www.econominctimes.com Avinash Celestin, March 18 2012 Natco victory could encourage other generic companies also to apply for compulsory licence. Patent wars are hard to wrap your head around, not least because it’s unclear what’s at stake for consumers. Apple, … Continue reading →

Posted in Compulsory Licensing | Tagged , , | Leave a comment

Natco examining other drugs to identify compulsory license targets

Posted on March 16, 2012 by

Source: www.economictimes.com Mar 15, 2012, 05.57PM IST Having won a landmark decision, Natco Pharma is collecting data to identify other life saving drugs where they can apply for compulsory licensing. The company chose Bayer’s drug Nexavar as the price of … Continue reading →

Posted in Compulsory Licensing, Indian Patent Law | Tagged , , , | Leave a comment

India issues compulsory licence for anti-cancer medicine

Posted on March 16, 2012 by

Source: TWN IP Info 15 March 2012 New Delhi:  (K.M. Gopakumar) – India’s Patent Office issued a compulsory license on Bayer’s anti-cancer medicine sorafenib tosylate on 12 March to a domestic manufacturer Natco Pharma, opening the door to a much … Continue reading →

Posted in Compulsory Licensing, HIV/Aids, Indian Patent Law, TRIPS | Tagged , , | 1 Comment